CN101411813B - Use of Chinese medicinal composition in preparing medicament for treating chronic systolic heart failure - Google Patents
Use of Chinese medicinal composition in preparing medicament for treating chronic systolic heart failure Download PDFInfo
- Publication number
- CN101411813B CN101411813B CN2007101632085A CN200710163208A CN101411813B CN 101411813 B CN101411813 B CN 101411813B CN 2007101632085 A CN2007101632085 A CN 2007101632085A CN 200710163208 A CN200710163208 A CN 200710163208A CN 101411813 B CN101411813 B CN 101411813B
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- medicine composition
- chinese medicine
- parched
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 67
- 239000000203 mixture Substances 0.000 title claims abstract description 35
- 208000008253 Systolic Heart Failure Diseases 0.000 title claims description 15
- 230000001684 chronic effect Effects 0.000 title abstract 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 12
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 12
- 235000008434 ginseng Nutrition 0.000 claims abstract description 12
- 238000011282 treatment Methods 0.000 claims description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- 229940079593 drug Drugs 0.000 claims description 19
- 239000000843 powder Substances 0.000 claims description 19
- 239000007788 liquid Substances 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 13
- 241001489978 Eupolyphaga Species 0.000 claims description 12
- 210000000582 semen Anatomy 0.000 claims description 12
- 241000208340 Araliaceae Species 0.000 claims description 11
- -1 filters Substances 0.000 claims description 10
- 239000002775 capsule Substances 0.000 claims description 7
- 238000010992 reflux Methods 0.000 claims description 6
- 239000006187 pill Substances 0.000 claims description 4
- 239000012141 concentrate Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 238000011084 recovery Methods 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 10
- 206010019280 Heart failures Diseases 0.000 abstract description 7
- 239000008280 blood Substances 0.000 abstract description 4
- 210000004369 blood Anatomy 0.000 abstract description 3
- 230000001502 supplementing effect Effects 0.000 abstract description 3
- 240000006766 Cornus mas Species 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 230000002936 tranquilizing effect Effects 0.000 abstract 1
- 230000004217 heart function Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000002861 ventricular Effects 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 208000019802 Sexually transmitted disease Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002398 materia medica Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 244000166124 Eucalyptus globulus Species 0.000 description 1
- 235000004692 Eucalyptus globulus Nutrition 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 235000010254 Jasminum officinale Nutrition 0.000 description 1
- 240000005385 Jasminum sambac Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- LXIUJOQXHQOBSX-UHFFFAOYSA-N acetic acid chloroethene Chemical compound ClC=C.ClC=C.CC(O)=O LXIUJOQXHQOBSX-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000002170 aldosterone antagonist Substances 0.000 description 1
- 229940083712 aldosterone antagonist Drugs 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960002233 benzalkonium bromide Drugs 0.000 description 1
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229940068811 digitalis preparation Drugs 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000009552 doppler ultrasonography Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- 210000001174 endocardium Anatomy 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000013210 hematogenous Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 208000004124 rheumatic heart disease Diseases 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides application of a traditional Chinese medicine composition in preparing a medicine for treating chronic retractable heart failure. The traditional Chinese medicine composition consists of twelve traditional Chinese medicines including ginseng, dogwood and nard, and has the efficacies of supplementing qi, nourishing yin, activating blood, dredging collaterals, clearing heart fire away and tranquillizing; and clinical trials prove that the medicine composition has good curative effect in treating chronic retractable heart failure.
Description
Technical field
The present invention relates to the application of a kind of Chinese medicine composition in preparation treatment systolic heart failure medicine, belong to the Chinese medicine application.
Background technology
Heart failure is a kind of clinical syndrome of complexity, is that any reason causes that cardiac structure and dysfunction cause cardiac pumping can not satisfy tissue metabolism's demand, or heart only could the normal pathological and physiological condition of pump blood under ventricular filling pressure rising situation.(core that declines prestige. the present Research of systolic heart failure. the special journal of the national doctor in self-important south, the 17th the 1st phase of volume of March in 2004)
The fundamental mechanism that development takes place heart failure is a remodeling ventricle, causes ventricular pump blood hypofunction, is that a kind of sexually transmitted disease (STD) of carrying out becomes, in case take place, later on even without new myocardial damage, clinically is in the stabilization sub stage, but self continuous progress still.In recent years, the western medical treatment systolic heart failure has had new treatment standard.The prolonged application angiotensin-convertion enzyme inhibitor, the patient of stable disease, share beta-blocker, add in case of necessity with aldosterone antagonists, digitalis preparation (yellow being good for, Xu Qiuxiang, single jasmine. therapy of combining Chinese and Western medicine systolic heart failure 42 examples. practical tcm internal medicine magazine, 2007 the 21st the 2nd phases of volume).But the treatment side effect of Western medicine is bigger, and Chinese medicine is being obtained certain achievement aspect the treatment systolic heart failure in recent years.Heart failure belongs to categories such as the traditional Chinese medical science " heart failure disease ", " cardiopalmus ", " obstruction of qi in the chest and cardialgia ", and its cause of disease, pathogenesis are the sick heart disease in place, and the cloudy consumption of the gas of the heart is hindered, and the deficiency of vital energy promotes unable, and deficiency of YIN venation is unfavorable, and hematogenous blockage causes stagnation of heart-blood.Medicine of the present invention has supplementing QI and nourishing YIN, promoting blood circulation to remove obstruction in the collateral, and the effect of clearing away heart-fire for tranquillization is used for the treatment of systolic heart failure clinically and has obtained curative effect preferably.
Chinese patent ZL 02146572.X discloses a kind of pharmaceutical composition for the treatment of Coronary heart disease ventricular early throb and preparation method thereof.The application of unexposed this medicine composite for curing systolic heart failure of this patent, the present invention have been done further research back and have been confirmed that Chinese medicine composition of the present invention is to treating systolic heart failure effectively on the basis of this patented technology.The disclosed content of Chinese patent ZL 02146572.X quotes in full at this.
Summary of the invention
The invention provides the application of a kind of Chinese medicine composition in preparation treatment systolic heart failure medicine, it is characterized in that this Chinese medicine composition is made by following bulk drugs:
Radix Ginseng 45-180 part, Radix Ophiopogonis 50-200 part, Fructus Corni 125-450 part, Radix Salviae Miltiorrhizae 125-450 part, Semen Ziziphi Spinosae (parched) 95-400 part, Herba Taxilli 95-400 part, Radix Paeoniae Rubra 45-200 part, Eupolyphaga Seu Steleophaga 35-150 part, Radix Et Rhizoma Nardostachyos 45-200 part, Rhizoma Coptidis 25-90 part, Fructus Schisandrae Sphenantherae 35-150 part, Os Draconis 75-300 part;
The weight ratio of crude drug is preferably in the Chinese medicine composition of the present invention:
89 parts of Radix Ginsengs, 112 parts of Radix Ophiopogonis, 224 parts of Fructus Corni, 224 parts of Radix Salviae Miltiorrhizaes, 186 parts of Semen Ziziphi Spinosae (parched)s, 186 parts of Herba Taxillis, 89 parts of Radix Paeoniae Rubra, 75 parts of Eupolyphaga Seu Steleophagas, 89 parts of Radix Et Rhizoma Nardostachyos, 45 parts of Rhizoma Coptidis, 67 parts of Fructus Schisandrae Sphenantheraes, 149 parts of Os Draconis;
The weight ratio of crude drug also is preferably in the Chinese medicine composition of the present invention:
45 parts of Radix Ginsengs, 112 parts of Radix Ophiopogonis, 224 parts of Fructus Corni, 225 parts of Radix Salviae Miltiorrhizaes, 186 parts of Semen Ziziphi Spinosae (parched)s, 186 parts of Herba Taxillis, 89 parts of Radix Paeoniae Rubra, 45 parts of Radix Et Rhizoma Nardostachyos, 35 parts of Eupolyphaga Seu Steleophagas, 45 parts of Rhizoma Coptidis, 67 parts of Fructus Schisandrae Sphenantheraes, 149 parts of Os Draconis;
The weight ratio of crude drug also is preferably in the Chinese medicine composition of the present invention:
90 parts of Radix Ginsengs, 135 parts of Radix Ophiopogonis, 270 parts of Fructus Corni, 200 parts of Radix Salviae Miltiorrhizaes, 150 parts of Semen Ziziphi Spinosae (parched)s, 150 parts of Herba Taxillis, 100 parts of Radix Paeoniae Rubra, 100 parts of Eupolyphaga Seu Steleophagas, 95 parts of Radix Et Rhizoma Nardostachyos, 60 parts of Rhizoma Coptidis, 75 parts of Fructus Schisandrae Sphenantheraes, 150 parts of Os Draconis;
In the application of the present invention, preparation technology that can be routinely (such as model Bi Ting " pharmacy of Chinese materia medica " (Shanghai Science Press 1997 December the 1st edition) record) handle the crude drug of Chinese medicine composition of the present invention to obtain its active component, preferably, the active component of this Chinese medicine composition can be made by the following step:
A) people participates in 8 times of amount 70% alcohol reflux three times, and merge extractive liquid, filters, and concentrates, and oven dry is ground into fine powder;
B) Fructus Schisandrae Sphenantherae, Fructus Corni, Radix Salviae Miltiorrhizae, Rhizoma Coptidis, Radix Et Rhizoma Nardostachyos add 8 times of amount 70% alcohol reflux 3 times jointly, and merge extractive liquid, filters, and reclaims ethanol;
C) Eupolyph aga sinesis Walker is broken into fine powder;
D) Radix Ophiopogonis, Semen Ziziphi Spinosae (parched), Herba Taxilli, Radix Paeoniae Rubra, Os Draconis decoct with water 2 times, and merge extractive liquid, filters, with the extracting solution merging behind the step b) recovery ethanol, simmer down to extractum;
E) with step d) gained extractum, add the fine drug powder of step c) gained, oven dry is ground into fine powder, adds step a) gained fine drug powder, and mixing promptly gets this Chinese medicine composition active component.
The invention also discloses that to contain above-mentioned Chinese medicine composition be capsule, tablet, electuary, powder, soft capsule, drop pill or oral liquid as the pharmaceutical preparation of active component.
In the Chinese medicine composition of the present invention, as the latin name of the crude drug of active component and processing method thereof from " Chinese medicine voluminous dictionary " (in July, 1977, front page, Shanghai science tech publishing house) and " Chinese pharmacopoeia (version in 2005, Chemical Industry Press).
Chinese medicine composition of the present invention can also be routinely preparation technology, for example, the preparation process of Fan Biting " pharmacy of Chinese materia medica " (Shanghai Science Press 1997 December the 1st edition) record, make the acceptable any conventional dosage form of pharmaceutics, for example capsule, tablet, electuary, powder, soft capsule, drop pill or oral liquid etc.For described dosage form can be realized, need when these dosage forms of preparation, to add the pharmacy acceptable auxiliary, for example: filler, disintegrating agent, lubricant, suspending agent, binding agent, sweeting agent, correctives, antiseptic, substrate etc.Filler comprises: starch, pregelatinized Starch, lactose, mannitol, chitin, microcrystalline Cellulose, sucrose etc.; Disintegrating agent comprises: starch, pregelatinized Starch, microcrystalline Cellulose, carboxymethyl starch sodium, crospolyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, cross-linking sodium carboxymethyl cellulose etc.; Lubricant comprises: magnesium stearate, sodium lauryl sulphate, Pulvis Talci, silicon dioxide etc.; Suspending agent comprises: polyvinylpyrrolidone, microcrystalline Cellulose, sucrose, agar, hydroxypropyl emthylcellulose etc.; Binding agent comprises, starch slurry, polyvinylpyrrolidone, hydroxypropyl emthylcellulose etc.; Sweeting agent comprises: saccharin sodium, Aspartane, sucrose, cyclamate, enoxolone etc.; Correctives comprises: sweeting agent and various essence; Antiseptic comprises: parabens, benzoic acid, sodium benzoate, sorbic acid and its esters, benzalkonium bromide, fixed, the Folium eucalypti globueli (Eucalyptus globulus Labill.) wet goods of acetic acid chloroethene; Substrate comprises: PEG6000, PEG4000, insect wax etc.
The consumption of Chinese medicine composition of the present invention by active component crude drug gross weight, is 7-28 gram/day, but takes every day once, preferably divides and takes for 2-4 time.
The specific embodiment
Following embodiment is used to illustrate the preparation of Chinese medicine composition of the present invention, but it can not constitute any restriction to scope of the present invention.
Embodiment 1
For the ease of the application of this Chinese medicine composition, this Chinese medicine composition is prepared as capsule
Write out a prescription: Radix Ginseng 89 restrains, restrain Radix Ophiopogonis 112, Fructus Corni 224 restrains, Radix Salviae Miltiorrhizae 224 restrains, Semen Ziziphi Spinosae (parched) 186 restrains, Herba Taxilli 186 restrains, Radix Paeoniae Rubra 89 restrains, Eupolyphaga Seu Steleophaga 75 restrains, Radix Et Rhizoma Nardostachyos 89 restrains, Rhizoma Coptidis 45 restrains, Fructus Schisandrae Sphenantherae 67 restrains, Os Draconis 149 restrain
Preparation method:
A) people participates in 8 times of amount 70% alcohol reflux three times, and 3 hours for the first time, each 2 hours later on, merge extractive liquid, filtered, and concentrates, and oven dry is ground into 80 order fine powders;
B) Fructus Schisandrae Sphenantherae, Fructus Corni, Radix Salviae Miltiorrhizae, Rhizoma Coptidis, Radix Et Rhizoma Nardostachyos add 8 times of amount 70% alcohol reflux 3 times jointly, and merge extractive liquid, filters, and reclaims ethanol;
C) Eupolyph aga sinesis Walker is broken into 80 order fine powders;
D) Radix Ophiopogonis, Semen Ziziphi Spinosae (parched), Herba Taxilli, Radix Paeoniae Rubra, Os Draconis decoct with water 2 times, and merge extractive liquid, filters, with the extracting solution merging behind the step b) recovery ethanol, simmer down to extractum;
E) with step d) gained extractum, add the fine drug powder of step c) gained, oven dry is ground into 80 order fine powders, adds step a) gained fine drug powder, mixing, 1000 capsules of packing into.
Usage and consumption: oral.One time 2～4,3 times on the one.
The test example
The clinical trial of traditional Chinese medicine composition for treating systolic heart failure of the present invention.
For illustrating the clinical efficacy of traditional Chinese medicine composition for treating systolic heart failure of the present invention, use the capsule (to call medicine of the present invention in the following text) that makes by embodiment 1 method to carry out following clinical trial.
1. physical data
Hebei Yi Ling hospital accepts for medical treatment altogether from year June in January, 2006-2007 and expands cardiopathia, coronary heart disease heart failure 244 examples, through clinical manifestation, surface electrocardiogram, ambulatory electrocardiogram, rabat, echocardiography, arrange attached rheumatic heart disease, congenital heart disease and other cardiomyopathy, and through the endocardium cardiac muscle close inspection and (or) coronary arteriography makes a definite diagnosis.According to NYHA grade scale scoring, III level heart merit 201 examples wherein, II level heart merit 43 examples, male's 140 examples, women's 104 examples are divided into treatment group and matched group at random.122 examples (male 70 examples, women 52 examples) are organized in treatment, age 50-82 year, II level heart merit 23 examples, III level heart merit 99 examples.Matched group 122 examples (male 68 examples, women 54 examples), age 48-80 year, II level heart merit 24 examples, III level heart merit 98 examples.Two groups of above each indexs of patient are compared there was no significant difference.
2. Therapeutic Method
Matched group adopts rest, oxygen uptake, the diuresis of limit sodium heart tonifying, ACE inhibitor, improve conventional therapy such as myocardial blood flow.The treatment group adds on the matched group basis with medicine of the present invention (Shijiazhuang Yiling Pharmaceutical Co., Ltd's production), and each 4, every day 3 times, 14 days was 1 course of treatment.
3. efficacy determination
Through 1 course of therapy, according to the increase evaluation cardiac function of patient CO (cardiac output), SV (stroke volume), CI (cardiac index), EF (ejection fraction) and exercise tolerance.Cardiac function improves the II level or the above person of II level is produce effects.Cardiac function improves the I level for effective.Cardiac function no change or deterioration are for invalid.
4. result
4.1 cardiac function
122 examples are organized in treatment, produce effects 81 examples (66.39%), effective 39 examples (31.9%), invalid 2 examples (1.6%), total effective rate 98.29%, 122 examples in the matched group, produce effects 57 examples (46.72%), effective 38 examples (31.1%), invalid 27 examples (22.1%), total effective rate 77.82%.Treatment group obvious effective rate and total effective rate are apparently higher than matched group, through X
2Check, P＜0.01.See Table 1
2 groups of cardiac function of table 1 are [example (%)] relatively
| Group | n | Produce effects | Effectively | Invalid | Total effective rate |
| Treatment group matched group | 122 122 | 81(66.39) 57(46.72) | 39(31.9) 38(31.1) | 2(1.6) 27(22.1) | 120(98.29) 95(77.82) |
4.2 heart color doppler ultrasonography kinetocardiogram ejection fraction (EF) relatively sees Table 2
Ejection fraction changes relatively before and after 2 groups of treatments of table 2
| Group | n | Before the treatment | After the treatment | Difference |
| Treatment group matched group | 122 122 | 47.30±10.76 46.93±11.30 | ?53.15±10.92?50.44±11.95 ** | -5.84±8.93 -3.52±8.34 |
Annotate:, compare P＜0.05 with matched group with preceding relatively P＜0.01 of treatment
4.3 toxicity treatment group viewing duration is not seen untoward reaction.
5. conclusion
Medicine of the present invention is made up of 12 flavor Chinese medicines such as Radix Ginseng, Fructus Corni, Radix Et Rhizoma Nardostachyos, has supplementing QI and nourishing YIN, promoting blood circulation to remove obstruction in the collateral, clearing away heart-fire for tranquillization, studies confirm that through modern pharmacology Radix Ginseng increases the energy reserve of depletion cardiac muscle by the protein of the depleted cardiac muscle of promotion and synthesizing of ATP.Above-mentioned clinical research shows that medicine of the present invention has good heart tonifying and improves the myocardial metabolism effect, has good curative effect for the treatment systolic heart failure.
Claims (7)
1. the application of Chinese medicine composition in preparation treatment systolic heart failure medicine is characterized in that this Chinese medicine composition is made by following bulk drugs:
Radix Ginseng 45-180 part, Radix Ophiopogonis 50-200 part, Fructus Corni 125-450 part, Radix Salviae Miltiorrhizae 125-450 part, Semen Ziziphi Spinosae (parched) 95-400 part, Herba Taxilli 95-400 part, Radix Paeoniae Rubra 45-200 part, Eupolyphaga Seu Steleophaga 35-150 part, Radix Et Rhizoma Nardostachyos 45-200 part, Rhizoma Coptidis 25-90 part, Fructus Schisandrae Sphenantherae 35-150 part, Os Draconis 75-300 part.
2. application as claimed in claim 1 is characterized in that, this Chinese medicine composition is made by following bulk drugs:
89 parts of Radix Ginsengs, 112 parts of Radix Ophiopogonis, 224 parts of Fructus Corni, 224 parts of Radix Salviae Miltiorrhizaes, 186 parts of Semen Ziziphi Spinosae (parched)s, 186 parts of Herba Taxillis, 89 parts of Radix Paeoniae Rubra, 75 parts of Eupolyphaga Seu Steleophagas, 89 parts of Radix Et Rhizoma Nardostachyos, 45 parts of Rhizoma Coptidis, 67 parts of Fructus Schisandrae Sphenantheraes, 149 parts of Os Draconis.
3. application as claimed in claim 1 is characterized in that, this Chinese medicine composition is made by following bulk drugs:
45 parts of Radix Ginsengs, 112 parts of Radix Ophiopogonis, 224 parts of Fructus Corni, 225 parts of Radix Salviae Miltiorrhizaes, 186 parts of Semen Ziziphi Spinosae (parched)s, 186 parts of Herba Taxillis, 89 parts of Radix Paeoniae Rubra, 45 parts of Radix Et Rhizoma Nardostachyos, 35 parts of Eupolyphaga Seu Steleophagas, 45 parts of Rhizoma Coptidis, 67 parts of Fructus Schisandrae Sphenantheraes, 149 parts of Os Draconis.
4. application as claimed in claim 1 is characterized in that, this Chinese medicine composition is made by following bulk drugs:
90 parts of Radix Ginsengs, 135 parts of Radix Ophiopogonis, 270 parts of Fructus Corni, 200 parts of Radix Salviae Miltiorrhizaes, 150 parts of Semen Ziziphi Spinosae (parched)s, 150 parts of Herba Taxillis, 100 parts of Radix Paeoniae Rubra, 100 parts of Eupolyphaga Seu Steleophagas, 95 parts of Radix Et Rhizoma Nardostachyos, 60 parts of Rhizoma Coptidis, 75 parts of Fructus Schisandrae Sphenantheraes, 150 parts of Os Draconis.
5. as each described application among the claim 1-4, it is characterized in that the active component of this Chinese medicine composition is made by the following step:
A) people participates in 8 times of amount 70% alcohol reflux three times, and merge extractive liquid, filters, and concentrates, and oven dry is ground into fine powder;
B) Fructus Schisandrae Sphenantherae, Fructus Corni, Radix Salviae Miltiorrhizae, Rhizoma Coptidis, Radix Et Rhizoma Nardostachyos add 8 times of amount 70% alcohol reflux 3 times jointly, and merge extractive liquid, filters, and reclaims ethanol;
C) Eupolyph aga sinesis Walker is broken into fine powder;
D) Radix Ophiopogonis, Semen Ziziphi Spinosae (parched), Herba Taxilli, Radix Paeoniae Rubra, Os Draconis decoct with water 2 times, and merge extractive liquid, filters, with the extracting solution merging behind the step b) recovery ethanol, simmer down to extractum;
E) with step d) gained extractum, add the fine drug powder of step c) gained, oven dry is ground into fine powder, adds step a) gained fine drug powder, and mixing promptly gets this Chinese medicine composition active component.
6. as each described application among the claim 1-4, it is characterized in that the preparation formulation of described Chinese medicine composition is capsule, tablet, electuary, powder, drop pill or oral liquid.
7. application as claimed in claim 5 is characterized in that, the preparation formulation of described Chinese medicine composition is capsule, tablet, electuary, powder, drop pill or oral liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007101632085A CN101411813B (en) | 2007-10-19 | 2007-10-19 | Use of Chinese medicinal composition in preparing medicament for treating chronic systolic heart failure |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007101632085A CN101411813B (en) | 2007-10-19 | 2007-10-19 | Use of Chinese medicinal composition in preparing medicament for treating chronic systolic heart failure |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101411813A CN101411813A (en) | 2009-04-22 |
| CN101411813B true CN101411813B (en) | 2011-12-28 |
Family
ID=40592691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007101632085A Active CN101411813B (en) | 2007-10-19 | 2007-10-19 | Use of Chinese medicinal composition in preparing medicament for treating chronic systolic heart failure |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101411813B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1403148A (en) * | 2002-10-24 | 2003-03-19 | 河北以岭医药研究院有限公司 | Medicines composition for treating coronary heart disease ventricular premature beat and its prepn |
-
2007
- 2007-10-19 CN CN2007101632085A patent/CN101411813B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1403148A (en) * | 2002-10-24 | 2003-03-19 | 河北以岭医药研究院有限公司 | Medicines composition for treating coronary heart disease ventricular premature beat and its prepn |
Non-Patent Citations (1)
| Title |
|---|
| 杨义航等.参松养心胶囊治疗慢性收缩性心力衰竭临床观察.《第三届国际络病学大会论文集》.2007,428-429. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101411813A (en) | 2009-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101632796B (en) | Application of Chinese medicinal composition in preparing medicament for treating acute heart failure | |
| CN102210844B (en) | Chinese medicinal composition for treating chronic hepatitis and preparation method thereof | |
| CN101607036B (en) | Application of Chinese medicinal composition on in preparing medicament for treating depression | |
| CN102961508A (en) | Traditional Chinese medicine composition used for treating prostatitis and benign prostatic hyperplasia | |
| CN104825788A (en) | Application of traditional Chinese medicine composition in preparation of drug for treating transient ischemic attack | |
| CN102908513B (en) | Application of traditional Chinese medicine composition in medicine for treating arrhythmia | |
| CN101653550B (en) | Chinese medicinal composition in preparation of medicament for treating type II diabetes | |
| CN101698050B (en) | Application of traditional Chinese medicine composite in preparing medicine treating paroxysmal atrial fibrillation | |
| CN101411813B (en) | Use of Chinese medicinal composition in preparing medicament for treating chronic systolic heart failure | |
| CN101632783B (en) | Application of Chinese medicinal composition in preparing medicament for treating cor pulmonale | |
| CN101632784B (en) | Application of Chinese medicinal composition in preparing medicament for treating acute myocardial infarction | |
| CN102210807B (en) | Application of traditional Chinese medicine composition in preparation of medicaments for treating angina pectoris | |
| CN101313990B (en) | Application of a Chinese medicinal composition in preparing medicament for treating neurosis | |
| CN101411764A (en) | Use of Chinese medicinal composition in preparing medicament for treating degenerative cardiac valve disease of old age | |
| CN101559161B (en) | Application of traditional Chinese medicine composition in preparing medicament for curing tristimania | |
| CN101411814B (en) | Use of Chinese medicinal composition in preparing medicament for treating intraventricular block | |
| CN101653548B (en) | Chinese medicinal composition in preparation of medicament for treating hypotension | |
| CN101683458B (en) | Application of a traditional Chinese medicine composition in preparation of medicament for treating vertigo | |
| CN102895514B (en) | Application of Chinese medicine composition in preparing medicines for treating pulmonary heart disease | |
| CN102861231A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating ventricular remodeling after myocardial infarction | |
| CN104940554A (en) | Chinese herbal composition for treating heart diseases | |
| CN101653549A (en) | Chinese medicinal composition in preparation of medicament for treating congestive heart-failure | |
| CN101396521B (en) | Use of traditional Chinese medicine composition in preparing medicine for treating cerebral circulation insufficiency | |
| CN102846931A (en) | Application of Chinese medicine composition in preparation of hyperthyroidism treatment drug | |
| CN101683459B (en) | Application of a traditional Chinese medicine composition in preparation of medicament for treating sleep disorder |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20231129 Address after: 102600 17 Tianfu street, Daxing biomedical industry base, Zhongguancun Science and Technology Park, Daxing District, Beijing Patentee after: BEIJING YILING PHARMACEUTICAL Co.,Ltd. Address before: 050035 No. 238 Tianshan Avenue, Shijiazhuang hi tech Development Zone, Hebei, China Patentee before: HEBEI YILING MEDICINE RESEARCH INSTITUTE Co.,Ltd. |